Worldwide Professional Acne Treatment Industry to 2030 - Rising Adoption of Acne Treatments is Driving Growth

News provided by

Nov 17, 2021, 14:30 ET

DUBLIN, Nov. 17, 2021 /PRNewswire/ -- The "Professional Acne Treatment Market Research Report: By Acne Type, Treatment Type, Professional Type - Global Industry Analysis and Demand Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

From $6,298.9 million in 2020, the global professional acne treatment market value is predicted to reach $13,124.5 million by 2030, at a 7.6% CAGR between 2020 and 2030, according to the market research report.

Key findings of this study

Treatments via devices to become rapidly popular in coming years
Professional treatment sought more commonly for inflammatory acne
Strong drug pipeline key driver for market growth
North America largest market for professional acne treatments
APAC to offer lucrative growth opportunities in future
Market fragmented due to presence of numerous companies

The COVID-19 pandemic had a negative effect on the professional acne treatment market as almost all the cosmeticians and dermatologists were forced to down their shutters, to comply with the lockdown protocols. Similarly, companies that produce drugs and devices for acne treatment were non-operational or functional at a rather small scale, which reduced the supply and trade of the products. On the demand side, people were discouraged from spending on non-essential stuff as many were under immense financial stress.

The coming years will be characterized by the faster growth of the inflammatory bifurcation in the professional acne treatment market, on the basis of acne type. This kind of acne is considered severer than the non-inflammatory type, and it is often painful. Additionally, inflammatory acne cannot be cured by most of the drugs available over the counter (OTC), which is why a professional's intervention is preferred.

The larger share in the treatment type segment of the professional acne treatment market in the past was held by the drugs bifurcation. Drugs are readily available, and treatment via them is less complex and costly than that carried out by devices.

Dermatologists are expected to dominate the professional acne treatment market in the near future, under segmentation by professional type. Compared to cosmeticians, dermatologists have a larger knowledge base and more experience in treating acne, which is why they remain popular among patients.

The market is being driven by the following factors:

Rising Prevalence of Acne: Almost 90% of the people on earth, especially young adults and adolescents, get acne at some point in their lives. Moreover, the Global Burden of Disease study estimates the 2019 incidence of this common dermatological issue at 50 million cases in the U.S. alone.
Adoption of Sedentary Lifestyle: This is another key driver for the professional acne treatment market as being less physically active leads to a rise in weight and the levels of lipids in the body. This, in turn, upsets the hormone concentration, which results in an array of skin diseases, including hormonal acne.

North America is the largest professional acne treatment market owing to the rising prevalence of this condition, increasing awareness on new drugs and devices, presence of many more drugs in the pipeline of pharma companies, such as Johnson & Johnson, Pfizer Inc., and Bausch Health Companies Inc., and high disposable income of the people of the continent.

The major players in the global professional acne treatment market are Galderma SA, Bausch Health Companies Inc., Johnson & Johnson, Pfizer Inc., Teva Pharmaceutical Industries Ltd., CHEPLAPHARM Arzneimittel GmbH, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Bayer AG, Almirall S.A., Candela Corporation, Lumenis Ltd., Alma Lasers Ltd., Sciton Inc., Cutera Inc., EL.EN. S.p.a., Venus Concept Inc., Fotona d.o.o., Erchonia Corporation, and InMode Ltd.

Key Topics Covered:

Chapter 1. Research Background

Chapter 2. Research Methodology

Chapter 3. Executive Summary

Chapter 4. Introduction
4.1 Definition of Market Segments
4.1.1 By Acne Type
4.1.1.1 Inflammatory
4.1.1.2 Non-inflammatory
4.1.2 By Treatment Type
4.1.2.1 Devices
4.1.2.1.1 Laser
4.1.2.1.2 IPL
4.1.2.1.3 Photopneumatic
4.1.2.1.4 Radiofrequency
4.1.2.1.5 Others
4.1.2.2 Drugs
4.1.2.2.1 Retinoids
4.1.2.2.2 Antibiotics
4.1.2.2.3 Hormonal agents
4.1.2.2.4 Combinations
4.1.3 By Professional Type
4.1.3.1 Cosmeticians
4.1.3.2 Dermatologists
4.2 Market Dynamics
4.2.1 Trends
4.2.1.1 Product launches and investments in R&D
4.2.1.2 Increasing number of strategic collaborations
4.2.2 Drivers
4.2.2.1 Rising adoption of acne treatments
4.2.2.2 Increasing prevalence of acne
4.2.2.3 Strong product pipeline
4.2.2.4 Adoption of sedentary lifestyle
4.2.3 Impact Analysis of Drivers on Market Forecast
4.2.4 Restraints
4.2.4.1 Side-effects associated with acne drugs
4.2.4.2 Availability of alternative treatments
4.2.5 Impact Analysis of Restraints on Market Forecast
4.2.6 Opportunities
4.2.6.1 Huge potential in emerging markets
4.3 Impact of COVID-19
4.4 Treatment Comparison
4.4.1 Devices
4.4.2 Drugs
4.5 Porter's Five Forces Analysis
4.5.1 Bargaining Power of Buyers
4.5.2 Bargaining Power of Suppliers
4.5.3 Intensity of Rivalry
4.5.4 Threat of New Entrants
4.5.5 Threat of Substitutes
4.6 Average Duration of Acne Treatment
4.7 Prevalence Rate of Acne
4.8 Number of Dermatologists
4.9 Average Treatment Price

Chapter 5. Global Market Size and Forecast
5.1 By Acne Type
5.2 By Treatment Type
5.2.1 Drugs Market, by Type
5.2.2 Devices Market, by Type
5.3 By Professional Type
5.4 By Region

Chapter 6. North America Market Size and Forecast

Chapter 7. Europe Market Size and Forecast

Chapter 8. APAC Market Size and Forecast

Chapter 9. RoW Market Size and Forecast

Chapter 10. Competitive Landscape
10.1 Major Offerings of Key Players
10.2 Recent Strategical Developments of Key Players
10.2.1 Product Launches and Approvals
10.2.2 Acquisitions and Mergers
10.2.3 Partnerships and Collaborations
10.3 Market Share Analysis of Key Players
10.3.1 U.S.
10.3.1.1 Drugs
10.3.1.2 Devices
10.3.2 Europe
10.3.2.1 Drugs
10.3.2.2 Devices
10.3.3 APAC
10.3.3.1 Drugs
10.3.3.2 Devices

Chapter 11. Company Profiles
11.1 Galderma SA
11.1.1 Business Overview
11.1.2 Product and Service Offerings
11.2 Johnson & Johnson
11.2.1 Business Overview
11.2.2 Product and Service Offerings
11.2.3 Key Financial Summary
11.3 Bausch Health Companies Inc.
11.3.1 Business Overview
11.3.2 Product and Service Offerings
11.3.3 Key Financial Summary
11.4 Pfizer Inc.
11.4.1 Business Overview
11.4.2 Product and Service Offerings
11.4.3 Key Financial Summary
11.5 CHEPLAPHARM Arzneimittel GmbH
11.5.1 Business Overview
11.5.2 Product and Service Offerings
11.6 Teva Pharmaceutical Industries Ltd.
11.6.1 Business Overview
11.6.2 Product and Service Offerings
11.6.3 Key Financial Summary
11.7 Sun Pharmaceutical Industries Ltd.
11.7.1 Business Overview
11.7.2 Product and Service Offerings
11.7.3 Key Financial Summary
11.8 Bayer AG
11.8.1 Business Overview
11.8.2 Product and Service Offerings
11.8.3 Key Financial Summary
11.9 Perrigo Company plc
11.9.1 Business Overview
11.9.2 Product and Service Offerings
11.9.3 Key Financial Summary
11.10 Almirall S.A.
11.10.1 Business Overview
11.10.2 Product and Service Offerings
11.10.3 Key Financial Summary
11.11 Lumenis Ltd.
11.11.1 Business Overview
11.11.2 Product and Service Offerings
11.12 Candela Corporation
11.12.1 Business Overview
11.12.2 Product and Service Offerings
11.13 Alma Lasers Ltd.
11.13.1 Business Overview
11.13.2 Product and Service Offerings
11.14 Cutera Inc.
11.14.1 Business Overview
11.14.2 Product and Service Offerings
11.14.3 Key Financial Summary
11.15 Sciton Inc.
11.15.1 Business Overview
11.15.2 Product and Service Offerings
11.16 EL.EN. S.p.a.
11.16.1 Business Overview
11.16.2 Product and Service Offerings
11.16.3 Key Financial Summary
11.17 Fotona d.o.o.
11.17.1 Business Overview
11.17.2 Product and Service Offerings
11.18 Venus Concept Inc.
11.18.1 Business Overview
11.18.2 Product and Service Offerings
11.18.3 Key Financial Summary
11.19 Erchonia Corporation
11.19.1 Business Overview
11.19.2 Product and Service Offerings
11.20 InMode Ltd.
11.20.1 Business Overview
11.20.2 Product and Service Offerings

Chapter 12. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/ufr1wi

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets